The combination of pembrolizumab plus the Bruton tyrosine kinase (BTK) inhibitor acalabrutinib was evaluated in 61 patients with r/r DLBCL with ≥1 prior therapy. This evidence concerns the gene BTK and diffuse large B-cell lymphoma.